Symposium des Deutschen Forschungsverbundes Blasenkarzinom e.V.

Margitta Retz(Arbeitsgemeinschaft Urologische Onkologie), Wolfgang A. Schulz(Heinrich Heine University Düsseldorf), P. Olbert(Philipps University of Marburg), A. Hartmann, Robert Stöhr(Friedrich-Alexander-Universität Erlangen-Nürnberg), Axel S. Merseburger(Universitäres Kinderwunschzentrum Lübeck), Roman Nawroth(TUM Klinikum)
Der Urologe
November 4, 2009
10.1007/s00120-009-2132-z
Cited by 1

Related Papers

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2017|1.4k
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a<i>BRCA1</i>or<i>BRCA2</i>Gene Alteration
|Journal of Clinical Oncology|2020|676